AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
Item 8.01. Other Events.
On May19, 2017, Amicus Therapeutics,Inc. (the Company) issued a
press release announcing the planned analysis of primary
endpoints in its Phase 3 Epidermolysis Bullosa Study. A copy of
this press release is attached hereto as Exhibit99.1.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits: The ExhibitIndex annexed hereto is incorporated
herein by reference.
|
Exhibit No. |
|
Description |
|
99.1 |
Press Release dated May19, 2017 titled Amicus Therapeutics |
About AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD)
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency. AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) Recent Trading Information
AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) closed its last trading session up +0.17 at 7.74 with 2,472,413 shares trading hands.
